A novel serum biomarker, clusterin, could be an early predictor of response to sorafenib
AASLD LiverLearning®, Takehisa Watanabe, 144139
Geographic variation and provider characteristics affect receipt of curative therapy in early stage hepatocellular carcinoma: a Veteran cohort study.
AASLD LiverLearning®, Marina Serper, 144140
Mixed lineage kinase 3 mediates the induction of CXCL10 by a STAT1-dependent mechanism during hepatocyte lipotoxicity
AASLD LiverLearning®, Kyoko Tomita, 144396
ALBI and PALBI Grade Predict Survival for HCC across Treatment Modalities and BCLC Stages in the MELD Era
AASLD LiverLearning®, Po-Hong Liu, 144141
The Molecular Progression Of Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Sophie Cazanave, 144397
Year 2 serum HBV DNA detectability predicts hepatocellular carcinoma in entecavir-treated patients - a 7-year cohort study of 1,680 patients with chronic hepatitis B
AASLD LiverLearning®, Grace Wong, 144142
The Dual Glucagon-Like Peptide-1 (GLP-1)/Glucagon Receptor Agonist MEDI0382 Improves Metabolic and Hepatic Indices of NASH in Mice
AASLD LiverLearning®, James Trevaskis, 144398
Decision Making for Surveillance Interval: Who May Extend Intervals 1 Year After Curative Treatments for Hepatocellular Carcinoma
AASLD LiverLearning®, Minjong Lee, 144155
A Novel Biomarker-Based Model for the Prediction of Response to Sorafenib and Overall Survival for Advanced Hepatocellular Carcinoma: A Prospective Cohort Study
AASLD LiverLearning®, Hwi Young Kim, 144156
CXCR3-/- mice are protected against nutrient excess diet-induced non-alcoholic steatohepatitis
AASLD LiverLearning®, Kyoko Tomita, 144412
Early decrease in alfafetoprotein as a prognosis factor of response in patients with advanced hepatocellular carcinoma treated with sorafenib
AASLD LiverLearning®, Teresa Ferrer Rios, 144157
Sevelamer hydrochloride treatment reverses steatohepatitis by attenuating mucosal inflammation and metabolic endotoxemia
AASLD LiverLearning®, Khalidur Rahman, 144413
Non-alcoholic fatty liver disease (NAFLD) is associated with low surveillance rate and advanced hepatocellular carcinoma (HCC) at diagnosis
AASLD LiverLearning®, Yi Huang, 144158
The dual FXR/TGR5 agonist INT-767 inhibits nonalcoholic steatohepatitis development in a rabbit model of metabolic syndrome
AASLD LiverLearning®, Luciano Adorini, 144414
Use of radiofrequency ablation and stereotactic body radiotherapy for the treatment of hepatocellular carcinoma: An analysis of the SEER-Medicare database
AASLD LiverLearning®, Neehar Parikh, 144171
The Burden of Liver Cancer in the United States Population
AASLD LiverLearning®, Aynur Unalp-Arida, 144172
Modulation of HMGB1 - NF-κB translocation by curcumin treatment ameliorates liver injury in non-alcoholic steatohepatitis-hepatocellular carcinoma mouse model
AASLD LiverLearning®, MST. REJINA AFRIN, 144428
Vitamin K supplementation decreased the incidence of severe hand-foot skin reaction during sorafenib treatment for hepatocellular carcinoma.
AASLD LiverLearning®, Yoshimichi Haruna, 144173
Fully human 3D cell culture model of non-alcoholic steatohepatitis
AASLD LiverLearning®, Tomasz Kostrzewski, 144429
L-Selectin (CD62L) drives development and progression of non-alcoholic steatohepatitis (NASH) in two dietary mouse models
AASLD LiverLearning®, Hannah Drescher, 144430
A cohort study of Hepatocellular Adenoma in post-menopausal women: can follow-up be safely terminated?
AASLD LiverLearning®, Anne Klompenhouwer, 144187
NOX1 Deletion Inhibits Hepatic Steatosis in db/db Model of Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Sebastian Larion, 144443
Hepatocyte-derived osteopontin promotes the development of hepatocellular carcinoma
AASLD LiverLearning®, Chuck Blajszczak, 144188
Suppression of chromatin-remodeling component Arid1a contributes to NASH and hepatocellular carcinoma through transcriptional dysregulation of lipogenesis.
AASLD LiverLearning®, Jen-Chieh Chuang, 144444
Role of Aberrant NDRG3 Expression in Human Hepatocellular Carcinoma
AASLD LiverLearning®, Jin Jeong, 144189
Saturated Fat Causes Non-Alcoholic Steatohepatitis through the Shifting of the Gut Microbiota to a Higher Endotoxemic profile
AASLD LiverLearning®, S.M.Touhidul Islam, 144445
Crystalized cholesterol leads to inflammasome activation and marks the transition from simple steatosis to steatohepatitis in humans with NASH and in mice with high-fat diet-induced steatohepatitis.
AASLD LiverLearning®, Angela Dolganiuc, 144446
Portal Hypertension SIG: Hypercoagulability in Cirrhosis: Program Chair : Introductory Remarks
AASLD LiverLearning®, Cristina Ripoll, 154693
Phenotypical characterization of intrahepatic cholangiocarcinomas : the more fibrous, the less pejorative.
AASLD LiverLearning®, Lorraine Blaise, 144203
Role of 12-Lipoxygenase in a Zebrafish Model of Non Alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Niharika Samala, 144459
SCCA-IgM helps to identify patients at risk of long-term hepatocelullar carcinoma
AASLD LiverLearning®, Javier Ampuero, 144204
Targeting Mitochondrial Pyruvate Metabolism to Ameliorate Hepatic Fibrosis in a Mouse Model of NASH
AASLD LiverLearning®, Brian Finck, 144460
Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort
AASLD LiverLearning®, Neehar Parikh, 144205
EDP-305, A Novel and Highly Potent Farnesoid X Receptor Agonist, Exerts Favorable Effects on Lipid Metabolism In Vitro
AASLD LiverLearning®, Lijuan Jiang, 144461
EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
AASLD LiverLearning®, Lijuan Jiang, 144462
RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers
AASLD LiverLearning®, James Hamilton, 154964
Kwashiorkor Malnutrition is Marked by Reduced Serum Concentrations of Essential Amino Acids
AASLD LiverLearning®, Thaddaeus May, 154965
Addition of simvastatin to carvedilol does not improve hemodynamic response in cirrhotics with varices without prior bleed: Preliminary results of an open label RCT
AASLD LiverLearning®, Arvind Rangarajan-Murali, 154966
Quality of Life and Outcomes after Multiple Courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Patients with Decompensated Cirrhosis
AASLD LiverLearning®, Virendra Singh, 154967
High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis
AASLD LiverLearning®, Helder Cardoso, 144219
APRI as a Tool to Initiate Increased Surveillance for HCC in African Americans
AASLD LiverLearning®, Paul Naylor, 144220
Pathophysiologic model of non-alcoholic fatty liver disease using precision-cut liver slices
AASLD LiverLearning®, Theerut Luangmonkong, 144476
Surveillance for Hepatobiliary Cancer in Primary Sclerosing Cholangitis
AASLD LiverLearning®, Navine Nasser-Ghodsi, 144221
A diet enriched in starch and oleate induces activation of NK cells and causes exaggerated suppression of de novo lipogenesis in adipose tissue, resulting in hepatic steatosis.
AASLD LiverLearning®, Caroline Duwaerts, 144477
MEDI0382, a dual GLP-1/glucagon receptor agonist, exerts beneficial effects on mitochondrial content and function in primary hepatocytes from lean and NASH mice
AASLD LiverLearning®, Michelle Beaton, 144478
Aroclor 1260 disrupts the hepatic proteome in the development of NASH
AASLD LiverLearning®, Josiah Hardesty, 144479
Hepatitis B and C as Risk Factors for Early Hepatocellular Carcinoma Across South America
AASLD LiverLearning®, Jose Debes, 144235
MELD score higher than 14 is the safety cutoff for patients with Child Pugh B or C cirrhosis undergoing drug-eluting beads chemoembolization for hepatocellular carcinoma.
AASLD LiverLearning®, castel helene, 144236
GPR91 antagonism: A novel approach for the treatment of nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Dhananjay Umrani, 144492
Is percutaneous approach better than endoscopic approach for successful biliary drainage in palliation of unresectable hilar cholangiocarcinoma: A meta-analysis and systematic review.
AASLD LiverLearning®, Abhiram Duvvuri, 144237
TRPV4 prevents tissue injury in diseased fatty liver by blocking CYP2E1-mediated redox-toxicity via Kupffer cell-induced nitric oxide production
AASLD LiverLearning®, Ratanesh Seth, 144493
Hepatocellular Nuclear Factor 4α (HNF-4α) activation by saRNA rescues dyslipidemia and promotes favorable metabolic profile in a high fat diet (HFD) fed rat model.
AASLD LiverLearning®, Vikash Reebye, 144494
Metabolomic classification of murine and human nonalcoholic fatty liver disease
AASLD LiverLearning®, Cristina Alonso, 144495
Hepatocellular Carcinoma is Independently Associated with Increased Mortality in Patients with Cirrhosis Admitted to Intensive Care Units
AASLD LiverLearning®, Christina Lindenmeyer, 144251
Outcomes of a new very small diameter drug eluting embolic beads for transarterial chemoembolization in unresectable hepatocellular carcinoma.
AASLD LiverLearning®, Mohamed Shoreibah, 144252
Poor Glycemic Control in Patients with Diabetes Increases the Risk of Hepatocellular Carcinoma
AASLD LiverLearning®, Jeffrey Nadelson, 144253
Febuxostat prevents diet-induced steatohepatitis and insulin resistance in mice: A comparison with allopurinol
AASLD LiverLearning®, Tomoki Nishikawa, 144509
Interleukin-33 influence the progression of NASH by acting on monocytes
AASLD LiverLearning®, Jingmin Zhao, 144510
Saroglitazar attenuates hepatic inflammation, oxidative stress and fibrosis in models of NAFLD/NASH
AASLD LiverLearning®, Mukul Jain, 144511
The hypoxia-mimetic agent CoCl2 induces proinflammatory and profibrotic signals as well as inflammasome activation in liver cells
AASLD LiverLearning®, Alejandra Hernández, 144512
Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States- a 4.5 Year Single-Center Experience
AASLD LiverLearning®, Gene Im, 144267
Factors Predicting Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Post-transplant Pathologic Stage
AASLD LiverLearning®, Brett Ecker, 144268
Factors Associated with Misdiagnosis of Hepatocellular Carcinoma before Liver Transplant with No Tumors Found on Explant: An Analysis of the UNOS database
AASLD LiverLearning®, Neil Mehta, 144269
Daclatasvir in combination with other DAAs achieves high rate of virological clearance with excellent safety profile in liver tranplanted patients for hepatitis C
AASLD LiverLearning®, Raffaella Lionetti, 144525
Variation in Demographics and Comorbidities in HCV Liver Transplant Recipients within UNOS Regions
AASLD LiverLearning®, George Cholankeril, 144526
100% Virological response with 3D regimen and significant short-term liver stiffness improvement in patients with recurrent hepatitis C following liver transplantation
AASLD LiverLearning®, Maria C. Speranta Iacob, 144527
Treatment of Hepatitis C with ledipasvir, sofosbuvir with or without ribavirin in post liver transplant patients in an academic center.
AASLD LiverLearning®, Merlin Punnoose, 144528
Kinetic AFP model analysis in patients awaiting liver transplantation (LT) for hepatocellular carcinoma (HCC): a risk factor for microvascular invasion and recurrence
AASLD LiverLearning®, Lucile Boivineau, 144283
Similar Donor and Recipient Outcomes After Left Lobe and Right Lobe Living Donor Liver Transplantation
AASLD LiverLearning®, Tiffany Wong, 144284
Hepatic venous outflow obstruction in polycystic liver disease: impact on pathology and intra and postoperative course after liver resection
AASLD LiverLearning®, Louise Barbier, 144285
Evaluating Liver Biopsy Predictors for Outcomes in Transplant Recipients with Cardiac/ Liver Disease
AASLD LiverLearning®, Tatyana Kushner, 144299
2-dimensional shear wave elastography rather than HVPG significantly improves MELD-Na to predict survival in decompensated cirrhosis patients
AASLD LiverLearning®, Maja Thiele, 144300
Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure (ACLF) with Hepatic Encephalopathy (HE): A Randomized Trial (ClinicalTrials.gov Identifier: NCT02321371)
AASLD LiverLearning®, Anand Kulkarni, 144301
Prevalence and Correlation of Diabetes with Severity of Chronic Liver Disease and Utility of HBA1C in these Patients as Compared with Oral Glucose Tolerance Test
AASLD LiverLearning®, Tejasav Sehrawat, 144315
Hepatocellular Carcinoma amongst Cirrhosis: Trends in Hospitalization and Inpatient Mortality in United States
AASLD LiverLearning®, Kalpit Devani, 144316
Early impaired neurological functioning after TIPS placement: a multimodal MRI studies
AASLD LiverLearning®, Marika Rudler, 144317
Palliative Care Utilization is Associated with Reduced Costs and Reduced Procedures in the Setting of Hepatocellular Carcinoma with Mortality: A Study of the National Inpatient Sample
AASLD LiverLearning®, Anne Liu, 144331
Prevalence, Predictors And Outcomes Of Hypoxic Hepatitis In Critically Ill Cirrhotics-A Single Center Prospective Study
AASLD LiverLearning®, RAKHI MAIWALL, 144332
Genomic Characterization of Stool Microbiota With Rifaximin Monotherapy Versus Lactulose Combination Therapy for Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
AASLD LiverLearning®, Herbert DuPont, 144333
FOXO3-dependent, M1-selective hepatic macrophage apoptosis is a normal mechanism that allows the liver to tolerate alcohol with minimal or no inflammation
AASLD LiverLearning®, Zhuan Li, 144091
Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the Hepatitis C Virus (HCV) Subgenomic Replicon System
AASLD LiverLearning®, Hua Tan, 144347
Restoration of bile acid homeostasis improves alcoholic liver disease in mice
AASLD LiverLearning®, Phillipp Hartmann, 144092
Towards a Single Treatment Cure for HCV: Reformulation of the Pan-genotypic NNI GSK2878175 as a Long Acting Parenteral (LAP) and In Vivo Proof of Concept
AASLD LiverLearning®, Martin Leivers, 144348
Osteopontin ablation drives hematopoietic stem cell mobilization and increases hepatic iron contributing to alcoholic liver disease
AASLD LiverLearning®, Fernando Magdaleno Verduzco, 144093
Pharmacokinetics (PK), safety and tolerability of the 2- and 3-direct acting antiviral (DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered once-daily (QD) in healthy volunteers (HVs)
AASLD LiverLearning®, Thomas Kakuda, 144349
Superior Long-Term Survival following Liver Transplantation in Patients with Alcoholic Liver Disease
AASLD LiverLearning®, George Cholankeril, 144094
The Role of Protein Carbonylation in Progression of Alcoholic Liver Disease in Male GSTA4-4 -/- Mice
AASLD LiverLearning®, Colin Shearn, 144107
Elevated plasma miR-24, miR-223, and PCSK9 levels in hepatitis C-infected patients who achieve a treatment-based viral cure
AASLD LiverLearning®, Anastasia Hyrina, 144363
PNPLA3 G/G genotype doubles the mortality risk of patients with portal hypertension due to fatty liver disease
AASLD LiverLearning®, Mattias Mandorfer, 144108
Patients failing all-oral interferon-free DAA regimens in Spain. Virological characterization of the HCVREsp cohort.
AASLD LiverLearning®, Federico Garcia, 144364
Hepatic Cell Death Caused by Fungi as well as Bacteria Is Mediated by ROS Induction of Nuclear Transglutaminase in Hepatic Cells
AASLD LiverLearning®, Soichi Kojima, 144109
Intrahepatic Th17/Treg interplay related to fibrosis in Chronic Hepatitis C
AASLD LiverLearning®, Daniela Rios, 144365
Acute Kidney Injury in Alcoholic Hepatitis: Prediction by Tachycardia and Impact on Short-term survival
AASLD LiverLearning®, Sujan Ravi, 144110
Acute Alcoholic Hepatitis has Comparable Survival following Liver Transplantation to Other Causes of Acute Liver Failure
AASLD LiverLearning®, George Cholankeril, 144123
Enhanced Natural Killer Cell Activity and Natural Resistance to Viral Infection amongst Irish Women Exposed to Hepatitis C Virus via Contaminated Anti-D Immunoglobulin
AASLD LiverLearning®, Mark Robinson, 144379
Excess Adiposity in Alcoholic Hepatitis Increases Mortality and Morbidity
AASLD LiverLearning®, Richard Parker, 144124
Immune regulation via the gut-liver axis plays a pivotal role in the pathogenesis of alcohol-induced liver disease
AASLD LiverLearning®, Shunsuke Shiba, 144125
Carcinoembryonic-antigen-related cell-adhesion molecule 1 is associated with the suppression of NK cells function in chronic hepatitis C.
AASLD LiverLearning®, Takahiro Suda, 144381
Therapeutic Potential Of Liver X Receptor (LXR) In Alcoholic Liver Disease (ALD)
AASLD LiverLearning®, Monideepa Sengupta, 144126
HCV Infection Induces Caspase Activation and Regulation of Telomerase Expression.
AASLD LiverLearning®, Huy TRAN, 144382